Pharmacological inhibition of kv1.3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues

American Journal of Physiology - Endocrinology and Metabolism

Volumn 301, Issue 2, 2011, Pages

  Straub, Stephen V ^a   Perez, Sylvie M ^a   Tan, B ^b   Coughlan, Kimberly A ^c   Trebino, Catherine E ^a   Cosgrove, Patricia ^a   Buxton, Joanne M ^a   Kreeger, John M ^c   Margaret Jackson, V ^a  

^a Cardiovascular Metabolic and Endocrine Diseases Research Unit   (United States)

^b Departments of Pharmacokinetics Dynamics and Metabolism   (United States)

^c PFIZER INC   (United States)

Author keywords

Adipose; Diabetes; Metabolism; Skeletal muscle

Indexed keywords

5 (4 PHENOXYBUTOXY)PSORALEN; GLUCOSE; MARGATOXIN; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CELL LINE; DONOR; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MOUSE; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE;

3T3-L1 CELLS; ADIPOSE TISSUE; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DIABETES MELLITUS, EXPERIMENTAL; FICUSIN; GLUCOSE; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; KV1.3 POTASSIUM CHANNEL; MICE; MUSCLE, SKELETAL; OBESITY; PATCH-CLAMP TECHNIQUES; POTASSIUM; SCORPION VENOMS;

EID: 79960818522     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00076.2011     Document Type: Article

References (31)

1. Aiyar J, Withka JM, Rizzi JP, Singleton DH, Andrews GC, Lin W, Boyd J, Hanson DC, Simon M, Dethlefs B, Lee CL, Hall JE, Gutman GA, Chandy KG. Topology of the pore-region of a K+channel revealed by the NMR-derived structures of scorpion toxins. Neuron 15: 1169-81, 1995.
2. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103: 17414-17419, 2006.
3. Bodendiek SB, Mahieux C, Hänsel W, Wulff H. 4-Phenoxybutoxysubstituted heterocycles-a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. Eur J Med Chem 44: 1838-1852, 2009.
4. Coetzee WA, Amarillo Y, Chiu J, Chow A, Lau D, McCormack T, Moreno H, Nadal MS, Ozaita A, Pountney D, Saganich M, Vega- Saenz de Miera E, Rudy B. Molecular diversity of K+channels. Ann NY Acad Sci 868: 233-285, 1999.
5. Desir GV. Kv1.3 potassium channel blockade as an approach to insulin resistance. Expert Opin Ther Targets 9: 571-579, 2005.
6. Doczi MA, Morielli AD, Damon DH. Kv1.3 channels in postganglionic sympathetic neurons: expression, function, and modulation. Am J Physiol Regul Integr Comp Physiol 295: R733-R740, 2008.
7. Fadool DA, Levitan IB. Modulation of olfactory bulb neuron potassium current by tyrosine phosphorylation. J Neurosci 18: 6126-6137, 1998.
8. Garcia-Calvo M, Leonard RJ, Novick J, Stevens SP, Schmalhofer W, Kaczorowski GJ, Garcia ML. Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. J Biol Chem 268: 18866-18874, 1993.
9. Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, Karmilowicz MJ, Auperin DD, Chandy KG. Pharmacological characterization of five cloned voltage-gated K+channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45: 1227-1234, 1994.
10. Guthoff M, Tschritter O, Berg D, Liepelt I, Schulte C, Machicao F, Haering HU, Fritsche A. Effect of genetic variation in Kv1.3 on olfactory function. Diabetes Metab Res Rev 25: 523-527, 2009.
11. Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson GA, Rudy B, Sanguinetti MC, Stühmer W, Wang X. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 57: 473-508, 2005.
12. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 245: 621-625, 1999.
13. Kalman K, Pennington MW, Lanigan MD, Nguyen A, Rauer H, Mahnir V, Paschetto K, Kem WR, Grissmer S, Gutman GA, Chris-tian EP, Cahalan MD, Norton RS, Chandy KG. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem 273: 32697-32707, 1998.
14. Li Y, Wang P, Xu J, Desir GV. Voltage-gated potassium channel Kv1.3 regulates GLUT4 trafficking to the plasma membrane via a Ca2+-dependent mechanism. Am J Physiol Cell Physiol 290: C345-C351, 2006.
15. Mackenzie AB, Chirakkal H, North RA. Kv1.3 potassium channels in human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 285: L862-L868, 2003.
16. Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA. Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J Neurosci 29: 6734-6751, 2009.
17. Mourre C, Chernova MN, Martin-Eauclaire MF, Bessone R, Jacquet G, Gola M, Alper SL, Crest M. Distribution in rat brain of binding sites of kaliotoxin, a blocker of Kv1.1 and Kv1.3 alpha-subunits. J Pharmacol Exp Ther 291: 943-952, 1999.
18. Nonaka N, Farr SA, Kageyama H, Shioda S, Banks WA. Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J Pharmacol Exp Ther 325: 513-519, 2008.
19. Panyi G, Vámosi G, Bacsó Z, Bagdány M, Bodnár A, Varga Z, Gáspár R, Mátyus L, Damjanovich S. Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc Natl Acad Sci USA 101: 1285-1290, 2004.
20. Pegoraro S, Lang M, Dreker T, Kraus J, Hamm S, Meere C, Feurle J, Tasler S, Prütting S, Kuras Z, Visan V, Grissmer S. Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett 19: 2299-2304, 2009.
21. Rabinovitch A. An update on cytokines in the pathogenesis of insulindependent diabetes mellitus. Diabetes Metab Rev 14: 129-151, 1998.
22. Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, Wulff H. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 68: 1254-1270, 2005.
23. Tschritter O, Machicao F, Stefan N, Schäfer S, Weigert C, Staiger H, Spieth C, Häring HU, Fritsche A. A new variant in the human Kv1.3 gene is associated with low insulin sensitivity and impaired glucose tolerance. J Clin Endocrinol Metab 91: 654-658, 2006.
24. Tucker K, Overton JM, Fadool DA. Kv1.3 gene-targeted deletion alters longevity and reduces adiposity by increasing locomotion and metabolism in melanocortin-4 receptor-null mice. Int J Obes (Lond) 32: 1222-1232, 2008.
25. Tucker K, Cavallin MA, Jean-Baptiste P, Biju KC, Overton JM, Pedarzani P, Fadool DA. The Olfactory Bulb: A Metabolic Sensor of Brain Insulin and Glucose Concentrations via a Voltage-Gated Potassium Channel. Results Probl Cell Differ 52: 147-157, 2010.
26. Vicente R, Escalada A, Villalonga N, Texidó L, Roura-Ferrer M, Martín-Satué M, López-Iglesias C, Soler C, Solsona C, Tamkun MM, Felipe A. Association of Kv1.5 and Kv1.3 contributes to the major voltage-dependent K+ channel in macrophages. J Biol Chem 281: 37675-3711685, 2006.
27. Villalonga N, Escalada A, Vicente R, Sánchez-Tilló E, Celada A, Solsona C, Felipe A. Kv1.3/Kv1.5 heteromeric channels compromise pharmacological responses in macrophages. Biochem Biophys Res Commun 352: 913-918, 2007.
28. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
29. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830, 2003.
30. Xu J, Koni PA, Wang P, Li G, Kaczmarek L, Wu Y, Li Y, Flavell RA, Desir GV. The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight. Hum Mol Genet 12: 551-559, 2003.
31. Xu J, Wang P, Li Y, Li G, Kaczmarek LK, Wu Y, Koni PA, Flavell RA, Desir GV. The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proc Natl Acad Sci USA 101: 3112-3117, 2004.